Number of MSM (number of couples) | 68 (34) |
Median age (range) | 27 (17–55)* |
HIV-positive (%) | 5 (7.6%) |
Median number of male partners in the last 3 months (IQR) | 3 (1–5) |
Condom use during anal sex in the last 3 months: number of MSM (%) | |
Always | 9 (14%) |
Sometimes | 40 (61%) |
Never | 14 (21%) |
No anal sex | 3 (5%) |
Declined to answer | 2 (3%) |
Sex overseas in the last 12 months: number of MSM (%) | |
Yes | 12 (18%)† |
No | 54 (82%) |
Declined to answer | 2 (3%) |
Number of culture-positive samples | 94 |
Median number per partner (IQR) | 1 (1–2) |
Median number per couple (IQR) | 3 (2–3) |
Sites with positive culture | |
Urethral | 32 |
Pharyngeal | 26 |
Rectal | 36 |
Urethral gonorrhoea within partnerships (n=34) | |
Either man was positive | 30 |
Both men were positive | 1 |
Pharyngeal gonorrhoea within partnerships (n=34) | |
Either man was positive | 19 |
Both men were positive | 4 |
Rectal gonorrhoea within partnerships (n=34) | |
Either man was positive | 24 |
Both men were positive | 5 |
Number of different molecular types | |
NG-MAST | 28 |
por alleles | 25 |
tbpB alleles | 18 |
MLST | 20 |
Antimicrobial resistance: number of isolates (MIC range, mg/L) | |
Penicillin DS/resistant | 92 (0.06–2.0) |
PPNG | 8 |
Ceftriaxone DS | 6 (<0.008–0.06) |
Azithromycin-resistant | 0 (≤0.06–0.25) |
Ciprofloxacin-resistant | 41 (≤0.03–16) |
Spectinomycin-resistant | 0 (≤64) |
*One patient’s age/date of birth was not available.
†2 New Zealand; 3 England; 2 Italy; 1 Thailand; 2 China; 1 USA; 1 unknown.
DS, decreased susceptibility; MIC, minimum inhibitory concentration; MLST, multilocus sequence typing; MSM, men who have sex with men; NG-MAST, N. gonorrhoeae multiantigen sequence typing; PPNG, penicillinase-producing N. gonorrhoeae.